Infobird Co., Ltd (NASDAQ: IFBD)

The QualityStocks Daily Newsletter would like to spotlight Infobird Co., Ltd (NASDAQ: IFBD).

Infobird (NASDAQ: IFBD), a software-as-a-service (“SaaS”) provider of artificial intelligence (“AI”) powered customer engagement solutions, was recently featured as a rare, undervalued and profitable SaaS gem. An article by SmallCapsDaily, a leading financial news website and publisher, provides an extensive overview of Infobird's progress as a global leader in the SaaS and cloud computing spaces. With its recent IPO in April 2021, Infobird continues to expand its base in SaaS while diversifying its interest. The company recently announced engagements with two major companies in the footwear and beauty cosmetics retail markets to provide a wide array of services. These include, but are not limited to, marketing, customer service support and digital customer engagement. Infobird’s diversification strategy, coupled with the opportunity to acquire other synergistic SaaS companies and the ability to quickly grow its clientele, positions the company as a unique and undervalued opportunity. To view the full press release, visit https://ibn.fm/898SN

Infobird Software (NASDAQ: IFBD), a software-as-a-service (“SaaS”) provider of AI-powered customer engagement solutions in China, offers holistic software solutions to support its growing corporate clientele deliver and manage customer engagement activities from beginning to end of the sales process; the company’s services even extend beyond to pre-sales and post-sales client support and involvement. Infobird combines its proprietary cloud computer structure with patented Voice over Internet Protocol (“VoIP”) and AI and machine learning capabilities as well as a no-code development platform for a flagship customer engagement offering unlike anything else in the industry. For more information, visit the company’s website at www.Infobird.com

Infobird Co., Ltd (NASDAQ: IFBD) is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. Infobird leverages a self-developed cloud computing structure, AI and machine learning capabilities, patented Voice over Internet Protocol (VoIP) application technologies, a no-code development platform and in-depth industry expertise to best serve its growing client base.

Founded in October 2001, Infobird empowers clients with value-driven business solutions designed to increase revenue, reduce costs and enhance service quality and customer satisfaction. The company currently specializes in corporate clients in finance and a broad array of ancillary industries.

Infobird is headquartered in Beijing, China, and began trading on the Nasdaq Capital Market on April 20, 2021, following an initial public offering of 6.25 million ordinary shares at a public offering price of $4.00 per share, before underwriting discounts and commissions.

Product Offering

Infobird’s flagship customer engagement software can handle both AI Customer Engagement and AI Salesforce Management.

• AI Customer Engagement
  • Intelligent Omni-Channel Customer Service – This offering allows clients to connect with their customers anytime and anywhere through a comprehensive suite of cloud-based tools.
  • Cloud Call Center – This service puts Infobird’s years of technical and operational experience to work for clients, with options including intelligent IVR technology, call monitoring, routing strategy and ticketing systems, all supported by multi-dimensional data reports.
  • Intelligent Telemarketing – Infobird’s AI bots can help clients navigate “never-ending lists” of potential customers, filter out the most promising leads and increase the working efficiency of agents, keeping agents focused on high-value tasks.
  • AI Voice Chatbot and AI Text Chatbot – This technology allows clients to create human-like interactions offering 24/7 availability and multi-round dialogue capabilities, decreasing labor costs by up to 80% while greatly improving efficiency.

• AI Salesforce Management
  • Intelligent Quality Inspection – Infobird’s platform aims to improve quality inspection rates and service levels through the use of real-time smart monitoring with comprehensive coverage.
  • Intelligent Training – Interactive training programs allow clients to ensure and continuously improve the performance level of their agents, lessening the impact of high turnover rates common throughout the customer service industry.

Infobird’s client base includes roughly 10,000 paid user accounts representing 358 customers in the industries of finance, education, public services, consumer products and health care – as reported on June 30, 2020.

Market Outlook

Cloud infrastructure services spending in China increased by 32% ($39.9 billion) in the fourth quarter of 2020. For all of 2020, total services grew to $142 billion, up from the reported $107 billion in 2019. This growth can be attributed to rising demand for cloud infrastructure over physical software solutions (https://ibn.fm/rHZUh). China is the second-largest market for cloud infrastructure solutions after the U.S., accounting for roughly 14% of the global industry.

Likewise, SaaS has demonstrated considerable growth potential in recent years. In 2020, the SaaS industry in China was valued at $3.3 billion, representing an increase of 43.5% over 2019, as companies continue to leverage artificial intelligence and Big Data technologies to increase efficiencies and promote expansion.

As one of the leading and longest standing providers of domestic SaaS solutions and with a comprehensive portfolio of intelligent, customizable and scalable solutions, Infobird is uniquely positioned to capitalize on the market’s expansion and resulting opportunities for corporate growth.

Management Team

Yimin Wu is the CEO and Founder of Infobird. He has served as the Chairman of the board of directors and Chief Executive Officer of the company since it was founded. From August 1990 to March 1993, Mr. Wu was a software engineer for the Software Center of Tsinghua University and was sent to the U.S. to co-develop the HP_UX operating system at HP Inc. From April 1993 to May 2000, he served as the general manager for Beijing Jing Zhou Computers Co. Ltd., a company responsible for marketing and developing interactive voice response systems. From July 2000 to October 2001, Mr. Wu was the general manager for Beijing Jing Zhou Rong Hua Internet Technology Co. Ltd, a company responsible for developing middleware for call center establishments. He received a bachelor’s degree and a master’s degree in computer sciences from Tsinghua University.

Hsiaochien Tseng is the EVP of Infobird and has held the title since January 2020. From March 2010 to September 2018, he served as a sales director for the Credit Card Center of China Guangfa Bank, where he was responsible for integrating and managing online and offline sales channels, establishing overall and regional sales strategies and creating training systems to increase the client base. From October 2018 to January 2020, Mr. Tseng served as SVP of Hua Tuo Digital Technology Group Co. Ltd., a financial information technology company. He received a bachelor’s degree in information management from Fu Jen Catholic University and a master’s degree in business administration from San Diego State University.

Chunhsiang Chen is the VP of Infobird, a position he has held since April 2012. From June 1990 to February 1993, he served as an advisory programmer of International Business Machine Corp. (IBM). During that time, he participated in the design and development of the Multiple Protocol Transport Network. From February 1993 to September 1996, Mr. Chen served as an associate professor in the Information Education Department of National Taiwan Normal University. He founded GenNet Technology Co. Ltd., an information technology company, in 1993 and served as the president until joining Infobird in 2012. Mr. Chen has a bachelor’s degree in computer sciences from the National Chiao Tung University and a master’s degree and doctoral degree in computer sciences from Northwestern University.

Lianfang Zhou is the CFO of Infobird and has been with the company for over 10 years. From September 2004 to July 2008, she served as the head of accounting at Beijing Saishuo Technology Co. Ltd., a software development company specializing in port services. From August 2008 to December 2009, Mrs. Zhou served as the head of accounting for Beijing Lianhe Lida Investment Co. Ltd., a property management services company. She holds an intermediate accounting qualification certificate issued by the Ministry of Finance of the PRC. Mrs. Zhou also has a bachelor’s degree in accounting from the Renmin University of China.

Infobird Co., Ltd (IFBD), closed Thursday's trading session at $3.83, up 2.957%, on 8,948,355 volume with 29,520 trades. The average volume for the last 3 months is 1.12M and the stock's 52-week low/high is $3.25/$11.25.

Recent News

• Infobird Co., Ltd (NASDAQ: IFBD) - InvestorNewsBreaks - Infobird Co. Ltd. (NASDAQ: IFBD) Featured in SmallCapsDaily Article
• Watch for Continued Losses in Shares of Infobird Co. Ltd (IFBD)
• Shares of Infobird Co. Ltd (IFBD) Have Fallen Below Previous 52-Week Low

Uranium Energy Corp. (NYSE American: UEC)

The QualityStocks Daily Newsletter would like to spotlight Uranium Energy Corp. (NYSE American: UEC).

NetworkNewsWire Editorial Coverage: Every president wants a legacy and President Joe Biden wants to put his stamp on climate change. Only a few months into his term, President Biden has pledged to slash U.S. greenhouse gas emissions by a minimum of 50–52 percent by 2030, an undertaking that doubles the nation’s prior promise under the 2015 Paris Climate Agreement. Further out, the target is net zero carbon emissions by 2050. These aggressive goals require immediate action, including addressing the fact that almost 40 percent all carbon dioxide pollution is created by power plants burning fossil fuels. The International Energy Agency ("IEA") recently published its comprehensive plan to cap the global temperature rise to 1.5°C by 2050, which includes a combination of wind, solar and nuclear to phase out fossil fuels. Today, the world is at a tipping point for the energy sector, presenting opportunities to capitalize on the epic transformation. In the United States, Uranium Energy Corp. (NYSE American: UEC) (Profile) is a leading player in low-cost and environmentally friendly in-situ recovery ("ISR") mining of uranium, the essential element that fuels nuclear energy.

Uranium Energy Corp. (NYSE American: UEC) is a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. Founded in 2003, UEC is headquartered in Corpus Christi, Texas. Properties acquired by the company are primarily located within the United States, including Texas, New Mexico, Colorado, Arizona and Wyoming.

Through the use of historical exploration data, UEC has been able to target and acquire properties that have already been subject to exploration and development by senior energy firms in the past.

UEC is well-financed to aggressively pursue key developmental targets. The company is also well-positioned to capitalize on rising global demand for more uranium and more carbon-free energy, and it uses technology that contributes to a cleaner environment.

In-Situ Recovery (ISR) Technology

In-situ recovery (ISR) technology is a low-cost and environmentally friendly mining technology utilized by UEC at its fully licensed projects, including Palangana, Burke Hollow, Goliad and Reno Creek.

ISR technology involves the circulation of naturally occurring and benign groundwater through a uranium ore body. This natural water (that is unfit for any other use) plus oxygen is pumped into injection wells through the uranium ore body, where the uranium in the host sandstone is oxidized and solubilized. The uranium bearing groundwater continues to flow through the sandstone to the extraction wells, where it is pumped to the surface. This water proceeds to an ion exchange unit (like a big water-softener) for uranium removal, then is pumped back to the wellfield and again re-circulated through the ore body. This recirculation of the same groundwater continues over and over, until the uranium in the sandstone is depleted.

In the ion exchange process, the extracted uranium in solution is concentrated on resin beads for transport to the Hobson Processing Facility. There, the uranium then undergoes several simple processing steps before being dried and packaged as “yellowcake” that will be transported to a conversion facility, where its sold to UEC customers.

Hobson Processing Plant

Hobson is the centerpiece in UEC’s hub and spoke production strategy, with low-cost satellite ISR operations all within relatively short trucking distance. The plant is fully licensed and currently on standby with an annual production capacity of 2 million pounds of U3O8. The spokes of the UEC strategy include the Palangana, Burke Hollow, Goliad, Salvo and Longhorn ISR projects. With an improvement in uranium prices that justify production, UEC plans to restart the plant with uranium loaded resins originating first from Palangana and then followed by Burke Hollow. UEC has applied for a license amendment with the Texas Commission on Environmental Quality to increase the Hobson facility’s production capacity to 4 million pounds per year.

Current Projects

Uranium Energy’s current project portfolio includes:

• Texas – Hobson Processing Plant, Palangana Mine, Goliad, Burke Hollow, Salvo and Longhorn
• Wyoming – Reno Creek
• Paraguay – Oviedo, Yuty and Alto Paraná
• New Mexico – Dalton Pass and C de Baca
• Colorado – Long Park and Slick Rock
• Arizona – Anderson, Los Cuatros and Workman Creek
• Canada – Diabase

Uranium Market Outlook

The long-term fundamentals underlying the market continue to strengthen. Currently, UEC sees an annual gap of about 40 million pounds between uranium production and utility requirements. Current forecasts show this structural deficit persisting at least through 2026 and then expanding further to almost 70 million pounds per year by 2030. While secondary supplies have been filling the void, those supplies are not a sustainable long term supply source. There are different estimates on timing, but it is clear secondary supply (that includes inventory drawdowns) will be insufficient to fill the projected gap between supply and demand, and new production will be required. As this transition evolves, the market will become more production cost driven as opposed to inventory driven.

Higher priced contracts that have supported high production costs are continuing to roll out of producer and utility supply portfolios. These higher priced contracts are not replaceable, with current market prices below production costs for the vast majority of western producers. This will likely continue the trend of production cuts and deferrals until prices rise sufficiently to sustain long-term mining operations.

In the U.S., some of the foreign State-Owned Enterprise (“SOE”) supply that has been flooding the market will be reduced. Last year, the U.S. Department of Commerce negotiated an amendment to the Agreement Suspending the Antidumping Investigation on Uranium from the Russian Federation that reduces America’s dependence on Russian natural uranium concentrates by up to 75% from prior levels. Due to a prolonged weak pricing environment from an influx of price insensitive supply from SOEs, U.S. production is effectively zero, less than 1% of U.S. requirements.

On the demand side of the equation, further upside market pressure also appears likely to evolve as utilities return to a longer-term contracting cycle to replace expiring contracts. Over the longer term, there continues to be underlying and increasing demand building, as the globe continues a push toward carbon-free energy goals. Those goals will require the 24/7, base load, clean energy that nuclear power provides as part of the overall supply mix. A good example of that policy messaging came from Japan’s energy minister, who recently said he considers nuclear energy “indispensable” if the country is to meet its net-zero carbon emission goals.

Exacerbating the overall supply picture, lead times for new production typically range from seven to 10 years or longer. The market appears to be within the time frames required for investment to bring new supply online to meet those lead times. However, prices are not yet at levels that incentivize future production, increasing the probability of the potential for less supply than the market is currently pricing in. All things considered, UEC believes the supply and demand fundamentals should continue to exert upward pressure on uranium prices.

Management Team

Spencer Abraham is Chairman of the Board for UEC. He served as the 10th U.S. Secretary of Energy from 2001 to 2005. He is an honors graduate of Michigan State University and Harvard Law School, and he was a law professor at the Thomas M. Cooley School of Law. He was elected chairman of the Michigan Republican Party in 1983 and later served as deputy chief of staff in the office of the vice president and as co-chairman of the National Republican Congressional Committee. In 1994, Mr. Abraham was elected to the United States Senate from Michigan and has also served as a director of Occidental Petroleum and as the non-executive chairman of AREVA’s U.S. board.

Amir Adnani is the Chief Executive Officer, President and Director of Uranium Energy. He advanced the company from concept to United States production within its first five years. Mr. Adnani has developed an extensive pipeline of low-cost and near-term production projects. He is the founder and Chairman of GoldMining Inc. (TSX: GOLD) (OTCQX: GLDLF), a gold-resources acquisition and development firm. He is also the Chairman of Uranium Royalty Corp. (TSX.V: URC). Mr. Adnani holds a Bachelor of Science from the University of British Columbia. He is a director of the University’s Alumni Association.

Scott Melbye is the company’s Executive Vice President. He is a 36-year veteran of the nuclear energy industry and has held numerous leadership positions in major uranium mining firms. He is also the current President, CEO and Director of Uranium Royalty Corp. He is an advisor to the Nuclear Energy Program at the Colorado School of Mines. Prior to his work at Uranium Participation Corp., Mr. Melbye worked for Cameco Inc. for 22 years. He received a Bachelor of Science in Business Administration with a specialization in International Business from Arizona State University in 1984.

Bruce Nicholson is the company’s Vice President of Corporate Development. He has spent 16 years as a specialist in the industry, serving major United States and European banks, broker-dealers and investment funds. Mr. Nicholson is a member of the Minerals Economics and Management Society, Minerals Industry Analyst Group, and the New York Society of Securities Analysts. He graduated with an MBA in Finance from Rutgers University in 1995 and is a CFA charter holder.

Uranium Energy Corp. (UEC), closed Thursday's trading session at $2.91, up 3.5587%, on 2,940,574 volume with 10,430 trades. The average volume for the last 3 months is 5.729M and the stock's 52-week low/high is $0.819999992/$3.67000007.

Recent News

• Uranium Energy Corp. (NYSE American: UEC) - 50% Reduction in Carbon Emissions by 2030 Means Opportunities Now
• InvestorNewsBreaks - Uranium Energy Corp. (NYSE American: UEC) Featured in NNW Editorial
• Best Mining Stocks To Buy This Week? 3 To Watch

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

• Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant growth projected looking forward.
• In the recent past, numerous studies have focused on the clinical application of psychedelics, including LSD, ayahuasca and psilocybin, in treating anxiety and depression disorders being conducted. For example, University of Zurich researchers have demonstrated that mindfulness meditation can improve the positive long-term effects of an individual dose of psilocybin, which can be found in magic mushrooms. Indeed, companies such as Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are developing psychedelic remedies for the most prevalent mental health conditions. It may be only a matter of time before these are available to patients.
• Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA, Laughren oversaw the review of all psychiatric drug-development activities conducted under Investigational New Drug (“IND”) as well as the review of all New Drug Applications (“NDAs”) and supplements for new psychiatric drug claims. He served for 29 years and received numerous awards for his regulatory accomplishments. To view the full press release, visit https://ibn.fm/QNWoZ

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Thursday's trading session at $2.07, up 2.4752%, on 1,009,132 volume with 1,460 trades. The average volume for the last 3 months is 405,733 and the stock's 52-week low/high is $0.493800014/$2.23499989.

Recent News

• Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) - InvestorNewsBreaks - Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board
• Researchers Find That Mindfulness Meditation Boosts Psilocybin's Beneficial Effects
• Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW).

AmpliTech Group (NASDAQ: AMPG) has secured a follow-on order for its low noise amplifier (“LNA”) technology. The order is from a Fortune 500 global defense and aerospace customer, and the products should ship in the third quarter of this year. AMPG is a designer, developer and manufacturer of state-of-the-art, signal-processing components for satellite and 5G communications networks. In the announcement, AmpliTech noted that its continued business progress in the past few months should enable favorable sequential and year-over-year revenue comparisons for the quarter ending June 30, 2021. With the economy reopening in the wake of COVID-19, the company anticipates its target industries and customers returning to previous business and procurement patterns and creating a growing range of revenue opportunities for the company. To view the full press release, visit https://ibn.fm/MfMAz

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

• Low Noise Amplifiers
• Cryogenic Amplifiers
• Limiting Amplifiers
• Waveguide Amplifiers
• Medium/High Power Amplifiers
• Surface Mount Amplifiers

Passive Components

• End Launch Rectangular Adapters
• Rectangular Adapter to COAX
• Power Dividers

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

• Timely technical assistance
• Little or no learning curve
• Less long-term costs associated with full-time employees with benefits and salaries
• Availability when necessary
• Customer support with schedules, project management and on the job training
• Access to technology
• Partnering for manufacturing and/or complete turn-key product solution
• Personal guidance from concept to development
• Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://nnw.fm/zqMEk). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://nnw.fm/rVzxX). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

• High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
• 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
• IoT (Internet of Things)
• Cloud Farms, Big Data and MEC architecture
• Quantum Supercomputers/Quantum Research
• Deep Space Astronomy
• Autonomous Self-Driving Vehicles
• Telemedicine, AR/VR (Augmented and Virtual Reality)
• Drones, UAVs (Unmanned Aerial Vehicles)
• Cyber-security
• Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Thursday's trading session at $4.99, up 1.8367%, on 766,955 volume with 3,062 trades. The average volume for the last 3 months is 704,415 and the stock's 52-week low/high is $0.879999995/$19.7999992.

Recent News

• AmpliTech Group Inc. (NASDAQ: AMPG) - InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Announces LNA Follow-On Order from Fortune 500 Global Defense Customer
• InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Announces Joint Venture with Data Protection, Encryption Solution Provider
• 3 (Almost) Penny Stocks Poised to Benefit From the Infrastructure BillPenny Stocks: AmpliTech Group (AMPG)UTStarcom (UTSI)Penny Stocks: Taseko Mines (TGB)More From InvestorPlace

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the company and its drug development pipeline, with his presentation scheduled to begin at 11:50 a.m. ET. In addition, McKee will contribute to a panel discussion on the future of research and development activities for psychedelic drug compounds. To view the full press release, visit https://ibn.fm/wUHVw

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Thursday's trading session at $0.4464, up 5.6818%, on 45,245 volume with 41 trades. The average volume for the last 3 months is 67,748 and the stock's 52-week low/high is $0.393599987/$1.03999996.

Recent News

• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit
• Could Psychedelics Be Used to Understand Near-Death Experiences?
• InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTC: NHHHF), a Canadian-based growth stage company committed to providing commercially viable and sustainable energy solutions, today issued an update to share the status of the company and its various initiatives. Among the highlights, the company reported a strong balance sheet for full funding of its Phase 2 Hydrogen-Ammonia Synthesizer commercial prototype systems, foundational intellectual property protection for its ammonia and hydrogen systems, as well as key additions to its growing team. FuelPositive also shared its plans to explore further complementary acquisitions to broaden its sustainability portfolio directly related to carbon free ammonia, power generation and enabling technologies. To view the full press release, visit https://ibn.fm/7NhDp

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

• Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
• Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
• End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Thursday's trading session at $0.1588, up 22.2479%, on 1,521,139 volume with 194 trades. The average volume for the last 3 months is 709,679 and the stock's 52-week low/high is $0.012/$0.326000005.

Recent News

• FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) - InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTC: NHHHF) Issues Corporate Update on Forward Progress of Several Initiatives
• InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTC: NHHHF) Closes on CAD$5M Private Placement, Featured in Syndicated Broadcast
• FuelPositive Announces Closing of CAD$5 Million Private Placement with U.S. Institutional Investors

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF)

The QualityStocks Daily Newsletter would like to spotlight Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF).

Marijuana tax collections in the state of Oregon have hit a new fiscal year record, having collected $15 million in April this year, which brings the total to about $146 million. Last year, the state of Oregon collected a total of roughly $133 million in taxes. At the start of the pandemic, marijuana sales in Oregon increased by 52% in the April to June period, in comparison with the April to June 2019 sales. In the two quarters that followed, increases of roughly 38% were also observed. Credit can be given to cannabis sector players such as Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) that have availed products found to be worthy enough by the state residents, hence the record-setting taxes paid with the purchases made.

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. Chalice Brands takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, Chalice Brands is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM).

Brands

Chalice Brands offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include:

Chalice(TM)
The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation.

Elysium Fields(TM)
Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience.

RXO(TM)
RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (EHO) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape).

GOLDEN(TM)
GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners.

Jackpot(TM)
Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time.

Financial Results

On May 25, 2021, Chalice Brands announced its financial results for the first quarter of 2021. Among the highlights, the company reported:

• Record quarterly revenues from continuing operations of $5.5 million, marking an 18% year-over-year increase compared to $4.7 million for the same period in 2020.
• Gross profit for the three-month period of $2.5 million on 45% gross margin, compared to $1.7 million in gross profit on a 37% gross margin in 2020.
• Its second consecutive quarter of positive adjusted EBITDA, recording approximately $370,000, or 7%, and continuing to demonstrate that the company’s Oregon operations are capable of covering corporate overhead costs.

In announcing the results, Jeff Yapp, CEO of Chalice Brands, stated, “Continued profitable operations and accretive acquisitions should set us up for a record breaking second half of 2021. We continue to look forward to favorable federal regulation changes while we grow Fifth & Root to showcase our brand portfolio nationally. Our team is energized and focused on growth as we remain disciplined in our allocation of capital.”

Cannabis Market Outlook

In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world.

As cannabis sales generally increased during the pandemic, Chalice Brands achieved record financials for Q4 2020, reporting quarterly revenue of $5.5 million, a year-over-year increase of 53%. The fourth quarter of 2020 also marked the company’s first quarter with positive adjusted EBITDA, reporting approximately $342,000 (https://ibn.fm/QMqrF).

Chalice Brands is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs.

Management Team

Jeff Yapp is the CEO and President of Chalice Brands Ltd. He has created a culture at Chalice Brands that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University.

John Varghese is the Executive Chair of Chalice Brands and is responsible for all capital markets initiatives at the company. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them.

Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments.

John Ford, Chalice Brands’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence.

Chalice Brands Ltd. (CHALF), closed Thursday's trading session at $0.9572, up 1.8298%, on 34,086 volume with 61 trades. The average volume for the last 3 months is 70,115 and the stock's 52-week low/high is $0.0502/$2.02629995.

Recent News

• Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) - 420 with CNW - Oregon Marijuana Tax Collection Shatters Annual Record with Two Months to Spare
• CannabisNewsBreaks - Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Eyes 'Record-Breaking Second Half of 2021'
• Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Earns BUY Rating, Coverage from Fundamental Research Corp

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Earlier last week China revealed its plans to hold an auction for industrial metals from its national reserves in an attempt to control commodity prices. The country’s National Food and Strategic Reserves Administration stated on its website that it would be releasing zinc, aluminum and copper to manufacturing and processing firms in the coming weeks. This notice comes at a time when Beijing is struggling to control a surge in the prices of different metals that was brought about by speculative buying; the surge has affected manufacturers’ margins, adequate global liquidity and post-pandemic economic recovery. Stability of prices is good for all metals sector players, including Asia Broadband Inc. (OTC: AABB). because it allows these companies to establish medium- to long-term plans without making too many assumptions, so the action China is taking could benefit the entire industry.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Thursday's trading session at $0.1302, up 15.2212%, on 27,045,254 volume with 1,985 trades. The average volume for the last 3 months is 29.386M and the stock's 52-week low/high is $0.002099999/$0.658999979.

Recent News

• Asia Broadband Inc. (OTC: AABB) - China to Stabilize Metals Prices by Releasing Reserves
• Asia Broadband Inc. (AABB) Enthused Over Preliminary Assay Results at LOI-target Gold Mine
• InvestorNewsBreaks - Asia Broadband Inc. (AABB) Announces Plans to Pursue AABBG Token Business Development in Central America

Healthtech Solutions Inc. (OTC: HLTT)

The QualityStocks Daily Newsletter would like to spotlight Healthtech Solutions Inc. (OTC: HLTT).

Healthtech Solutions (OTC: HLTT) is positioning itself to be a leader in the burgeoning precision oncology market — projected to grow at a 9.9% CAGR from 2019 to 2027 and reach an estimated $99.7 billion — as a result of its newest acquisition: Varian Biopharmaceuticals. Varian is a precision oncology company developing novel therapeutics for the treatment of cancer — a proprietary atypical protein kinase C iota (“aPKCi”) inhibitor for the treatment of various tumor types. Its drug candidates, VAR-101 and VAR-102, leverage the company’s expertise. To view the full article, visit https://ibn.fm/MKKvp

Healthtech Solutions Inc. (OTC: HLTT), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

Healthtech Solutions Inc. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of Healthtech Solutions Inc. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of Healthtech Solutions Inc. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of Healthtech Solutions Inc. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of Healthtech Solutions Inc. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

Healthtech Solutions Inc. (HLTT), closed Thursday's trading session at $1.14, up 48.0327%, on 977 volume with 5 trades. The average volume for the last 3 months is 8,587 and the stock's 52-week low/high is $0.041499998/$4.00.

Recent News

• Healthtech Solutions Inc. (OTC: HLTT) - InvestorNewsBreaks - Healthtech Solutions Inc. (HLTT) Positioning at Leading Edge of Cancer Treatment
• Healthtech Solutions Inc. (HLTT) Initiates Incubator Model to Develop Powerful Biotech and Medtech Portfolio
• As Investments Opportunities Pile Up for Its Biotech Portfolio Model Strategy, Healthtech Solutions Inc. (HLTT) Taps New CEO After First Acquisition

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF)

The QualityStocks Daily Newsletter would like to spotlight PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF).

Collaboration between PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) and Venus Williams is one of the powerful alignment of core values. As someone who has overcome considerable health barriers in her sports journey with the help of a vegan diet, she is a natural fit for PlantX as a company dedicated to making plant-based living accessible to consumers.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) aims to redefine the plant-based community through e-commerce, with a core objective of becoming the most trusted and convenient destination for people living plant-based lives. PlantX is a multifaceted marketplace providing consumers all things plant-based ranging from an efficient e-commerce experience, connecting consumers with interactive PlantX brick-and-mortar stores, and a PlantX home delivery system for products, meals, recipes and more.

PlantX is a high-growth technology company focusing on consumer-packaged goods (“CPG”) for the plant-based opportunity. The PlantX platform aims to serve as the digital face of this community with its one-stop-shop for everything plant-based, including:

• An easy-to-use e-commerce shopping experience featuring the following:
• Plant-based grocery items (from all your pantry needs to vitamins, cosmetics and even pet food)
• Meal delivery with recipes created by well-known plant-based chefs throughout the world
• Plant shop – delivering a wide variety of affordable indoor houseplants to homes across Canada and the U.S.
• Easy to follow plant-based recipes every week
• Partnerships with restaurants, nutritionists, chefs and brands
• A community of like-minded individuals
• State-of-the-art flagship PlantX locations

Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features over 10,000 items across diverse product categories such as pantry items, beverages, personal care, pet food and indoor plants. In addition, PlantX has collaborated with renowned chefs and nutritionists to create 20 unique and pre-made meals delivered to the comfort of your own home.

Headquartered in Vancouver, Canada, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and wellbeing, raise plant-based awareness in a hyper-palatable world, connect with global consumers and forge a welcoming plant-based community.

The company currently reports 4 million stock options and 24 million warrants outstanding, with a total of 88,832,159 shares issued and outstanding and a total market cap of $89.9 million on January 18, 2021. PlantX has continued to catalyze its capital markets dynamics by applying to list its common shares on the Nasdaq Capital Market (“NASDAQ”). The company’s common shares are eligible for electronic clearing and settlement through The Depository Trust Company (“DTC”) in the United States.

Market Outlook

With its comprehensive e-commerce platform, PlantX is strongly positioned for a prominent role in the fast-growing plant-based food market, e-commerce and the online food delivery sectors. The global plant-based food market is expected to reach $74.2 billion by 2027, expanding at a CAGR of 11.9%. Similarly, the online food delivery market has steadily grown, especially during the current pandemic. This trend seems here to stay. In the United States alone, the sector is expected to report $28.5 billion by 2024, with companies such as UberEats experiencing 152% increases in food deliveries in the summer of 2020.

Complementary to these trends, and as a result of the COVID-19 pandemic, online sales and digitization have also both grown exponentially in 2020. Grocery shopping has seen a remarkable transition to e-commerce, with online grocery sales growing by 53% in 2020. Amid the pandemic-imposed physical interactions and related consumer behavior change, large retailers have been compelled to meet this surge in e-commerce demand. For example, Whole Foods Markets has increased its online sales capacity by over 60% in 2020. The global meal kit delivery system is also becoming increasingly popular and is expected to achieve a market value of $19.92 billion by 2027, expanding at a CAGR of 12.8%.

PlantX aims to capitalize on this anticipated exponential market growth of the plant-based, e-commerce and home-delivery industries.

Digital Platform for the Plant-Based Community

The digital interface provided by PlantX spans a health and wellness initiative that offers thousands of plant-based products, meal delivery, indoor plants, recipes and a community space for those who are like-minded about plant-based products and healthy lifestyles. PlantX has been compared to Amazon, except with a focused tailored selection of plant-based offerings.

PlantX provides everything a consumer needs for plant-based living at the click of a button. With PlantX, customers can:

• Shop
• Find recipes
• Read blogs
• Join a community forum
• Listen to podcasts
• View cosmetics
• Research vitamins
• Purchase plant-based pet foods
• Read corporate updates
• Subscribe to an insightful newsletter

The company’s website was designed with a user-friendly interface that allows customers to visit the site and easily find what they need. Forums for communicating with a plant-based community make it easier to swap recipes or locate the best restaurants serving vegan and vegetarian-friendly cuisine.

PlantX Flagship Locations – British Columbia (Canada), San Diego (California), & the State of Israel

PlantX will link the e-commerce platform to flagship brick-and-mortar stores for a highly sensory customer experience. This is anticipated to drive corporate growth and global brand recognition.

These PlantX branded flagship locations will first launch in:

• Squamish, British Columbia, Canada
• San Diego, California, United States
• Tel Aviv, State of Israel

Customer engagement, education and creating a global plant-based community will be furthered through this initiative.

PlantX Restaurant Partnerships

With consumers becoming better informed and more health and environmentally conscious, a growing number of restaurants will start catering to the needs of customers who are vegan, vegetarian, have food-allergies (or specialized diets), or simply want to eat healthier.

PlantX proactively aims to support this change and help restaurants meet the needs of the plant-based community. Restaurants that want to increase revenue, drive traffic and make an impact can therefore partner with PlantX to better serve their customers by expanding and refining their menus.

Future Goals for PlantX Life

Having successfully completed all of the milestones that PlantX had set-out to achieve in the second half of 2020, PlantX strives to continue scaling through organic growth, strategic partnerships and accretive M&A opportunities. The upcoming plans from PlantX includes a global expansion strategy for distribution in North America, Europe and Israel.

Verticals launched in 2020 include:

• New meals and programs by renowned chefs
• Flagship PlantX locations
• PlantX branded goods
• United States meal delivery and LIV
• Online peer-to-peer fitness

Management Team

Sean Dollinger, the Founder of PlantX Life Inc., has had a very active professional career that started when he was only 17. While still in college, he started a delivery service that soon became one of Canada’s largest delivery firms (before companies like Postmates and Uber Eats ever existed). In 2014, Mr. Dollinger founded Namaste Technologies, the largest international e-commerce distributor of vaporizers and accessories. He brought Namaste public and turned it into a $1.2 billion business in two years. After finding a plant-based diet himself, and seeing the massive benefits that it provided for him, he decided he wanted to find a way to give back to the community and focus on something he loves. PlantX Life was born from this desire and became his passion project. He truly walks the talk.

Julia Frank is the CEO of PlantX Life. She has an MBA in digital entrepreneurship, and, in her past roles, she set up renowned strategies for large corporations like BMW and Daimler in Germany. Beyond her professional business prowess, Ms. Frank finds tremendous joy in preparing delicious and nutritious plant-based meals and is the face of the company. She practices a healthy and active lifestyle that includes experiencing as many cultures as possible to add more knowledge of the industry at large. This globally inclusive perspective gives her the unique advantage of being able to see plant-based living from all angles.

Lorne Rapkin, CPA, CA, LPA, is the President and CFO of PlantX Life and is also a partner at Rapkin Wein LLP. He has experience with clients in almost every industry, including finance, professional services, real estate, automotive, media and manufacturing. Mr. Rapkin works very closely with investment and public firms, seeking to comply with IFRS accounting standards. His roles often require him to work with management on go-public transactions, acquisitions and mergers. His keen attention to detail is an asset to any client he works with, and PlantX is no exception.

Alex Hoffman is the company’s CMO and has spent the last 10 years in the creative field cultivating her passion for design and appreciation for beauty. This is apparent in all of the creative decisions and outcomes seen at PlantX. Her role within the company is to oversee all of the brand marketing activities, establish and execute key processes for rapid growth, and work closely with management to refine the brand’s message for key segments and emerging opportunities. She has a sharp vision for exactly what’s needed to convey the company’s core messages and principles to both the public and investors, and she is a visionary with respect to creative marketing ideas and concepts.

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), closed Thursday's trading session at $0.402401, up 5.895%, on 97,906 volume with 110 trades. The average volume for the last 3 months is 206,688 and the stock's 52-week low/high is $0.349999994/$1.85000002.

Recent News

• PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) - Vegan Sport Icon Venus Williams and PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) Committed to Creating Plant-Based Ecosystem; Empower Consumers to Embrace Plant-Based Living
• InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) CEO Discusses Following Passion in Optimal Self Conversations Interview
• InvestorNewsBreaks - PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Launches Products on Walmart Canada Marketplace

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

• As the U.S. government appears to be throwing support and assistance behind efforts to limit its dependence on other countries for the mining and production of various metals, Energy Fuels (NYSE American: UUUU) (TSX: EFR) is increasing its efforts to produce commercial rare earth elements (“REEs”), as well as continue its commitment to uranium production, recycling and environmental and social responsibility (https://ibn.fm/XBT1k).
• Energy Fuels (NYSE American: UUUU) (TSX: EFR) is collaborating with Carester SAS, a leading global expert on rare earth separation, in its ongoing commitment to developing its rare earth element (“REE”) business. As part of this effort, the companies are working to conduct a scoping study for the development of a solvent extraction REE separation circuit at Energy Fuels’ White Mesa Mill in Utah. To view the full article, visit https://ibn.fm/bytG8

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

• White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
• Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
• Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

• Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
• Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
• Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

• La Sal Complex (Utah)
• Whirlwind Mine (Colorado/Utah)
• Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday's trading session at $6.60, up 5.6%, on 3,469,953 volume with 14,690 trades. The average volume for the last 3 months is 3.641M and the stock's 52-week low/high is $1.41999995/$7.82999992.

Recent News

• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) - MiningNewsBreaks - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), Carester Collaborate to Build Fully Integrated Rare Earth Supply Capabilities
• Energy Fuels (NYSE American: UUUU) (TSX: EFR) Ramps Up REE Production
• Mineral Sponges May Help Absorb Residual Uranium from Contaminated Sites

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO DIGITAL, a premier international biotech partnering event held virtually on June 10-11 & 14-18, 2021. The Predictive Oncology companies attended the event during the second leg of the conference.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

• A database of clinically validated historical and outcome data from patient tumors
• An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
• A “smart” patient-derived tumor profiling platform
• An in-house bioinformatics artificial intelligence (AI) platform
• A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
• An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $1.09, up 5.8252%, on 2,529,076 volume with 5,522 trades. The average volume for the last 3 months is 2.882M and the stock's 52-week low/high is $0.629999995/$2.29999995.

Recent News

• Predictive Oncology (NASDAQ: POAI) - Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference
• Predictive Oncology Inc.'s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer
• Analysis Uncovers Kidney Cancer Development, Response to Treatment